Clinical-stage drug discovery, development and manufacturing company Sutro Biopharma Inc (NASDAQ: STRO) disclosed on Wednesday that James P Panek has been appointed to its board of directors.
With over 40 years of experience in the biotech and pharmaceutical industry, Panek has worked as an independent consultant since 2011.
Previously, Panek held leadership positions at VaxGen, from 2002 to 2010. While at VaxGen, Panek served as co-ceo and chairman of its international joint venture, Celltrion. He was appointed chief executive officer at VaxGen in 2007.
Panek also held several leadership positions during an 18-year tenure at Genentech.
Sutro Biopharma is focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics. To date, Sutro has designed cytokine-based immuno-oncology therapies, ADCs, vaccines and bispecific antibodies primarily directed at clinically-validated targets for which the current standard of care is suboptimal.
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV